1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease.
Lancet 2017;389:1238–1252.
2. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury.
Compr Physiol 2012;2:1303–1353.
3. Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment.
Kidney Int 2006;70:1120–1126.
4. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.
J Am Soc Nephrol 2005;16:3365–3370.
5. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis.
Clin J Am Soc Nephrol 2013;8:1482–1493.
6. Zager RA, Baltes LA, Sharma HM, Jurkowitz MS. Responses of the ischemic acute renal failure kidney to additional ischemic events.
Kidney Int 1984;26:689–700.
7. Bonventre JV, Basile D, Liu KD, et al. AKI: a path forward.
Clin J Am Soc Nephrol 2013;8:1606–1608.
8. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.
Kidney Int 2012;81:442–448.
9. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.
J Immunol 1986;136:2348–2357.
10. Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo cd4+ T cell differentiation and function: revisiting the Th1/Th2 paradigm.
Annu Rev Immunol 2020;38:705–725.
11. Yu SL, Kuan WP, Wong CK, Li EK, Tam LS. Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus.
Clin Dev Immunol 2012;2012:715190.
12. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
Nat Immunol 2005;6:1123–1132.
13. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
Nat Immunol 2005;6:1133–1141.
14. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease.
Immunity 2019;50:892–906.
15. Bhaumik S, Basu R. Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response.
Front Immunol 2017;8:254.
16. Zhang S. The role of transforming growth factor β in T helper 17 differentiation.
Immunology 2018;155:24–35.
17. Ciofani M, Madar A, Galan C, et al. A validated regulatory network for Th17 cell specification.
Cell 2012;151:289–303.
18. Derler I, Jardin I, Romanin C. Molecular mechanisms of STIM/Orai communication.
Am J Physiol Cell Physiol 2016;310:C643–C662.
19. Kaufmann U, Kahlfuss S, Yang J, Ivanova E, Koralov SB, Feske S. Calcium signaling controls pathogenic Th17 cell-mediated inflammation by regulating mitochondrial function.
Cell Metab 2019;29:1104–1118.
20. Feske S, Picard C, Fischer A. Immunodeficiency due to mutations in ORAI1 and STIM1.
Clin Immunol 2010;135:169–182.
21. Kim KD, Srikanth S, Tan YV, et al. Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation.
J Immunol 2014;192:110–122.
22. Mehrotra P, Sturek M, Neyra JA, Basile DP. Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury.
J Clin Invest 2019;129:4951–4961.
23. Gaffen SL. Structure and signalling in the IL-17 receptor family.
Nat Rev Immunol 2009;9:556–567.
24. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy.
Cytokine 2008;41:92–104.
25. Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F.
J Immunol 2007;179:5462–5473.
26. Biswas PS. IL-17 in renal immunity and autoimmunity.
J Immunol 2018;201:3153–3159.
27. Cypowyj S, Picard C, Maródi L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans.
Eur J Immunol 2012;42:2246–2254.
28. Sundac L, Dando SJ, Sullivan MJ, Derrington P, Gerrard J, Ulett GC. Protein-based profiling of the immune response to uropathogenic Escherichia coli in adult patients immediately following hospital admission for acute cystitis.
Pathog Dis 2016;74:ftw062.
29. Sivick KE, Schaller MA, Smith SN, Mobley HL. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection.
J Immunol 2010;184:2065–2075.
30. Olson PD, Hruska KA, Hunstad DA, Lacerda Mariano L. Androgens enhance male urinary tract infection severity in a new model.
J Am Soc Nephrol 2016;27:1625–1634.
31. Zychlinsky Scharff A, Rousseau M, et al. Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection.
JCI Insight 2019;5:e122998.
32. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice.
J Infect Dis 2004;190:624–631.
33. Ramani K, Jawale CV, Verma AH, Coleman BM, Kolls JK, Biswas PS. Unexpected kidney-restricted role for IL-17 receptor signaling in defense against systemic Candida albicans infection.
JCI Insight 2018;3:e98241.
34. Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus.
Arthritis Res Ther 2010;12:R53.
35. Jakiela B, Kosałka J, Plutecka H, Bazan-Socha S, Sanak M, Musiał J. Facilitated expansion of Th17 cells in lupus nephritis patients.
Clin Exp Immunol 2018;194:283–294.
36. Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis: association to histopathology and response to treatment.
BMC Immunol 2015;16:7.
37. Crispín JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.
J Immunol 2008;181:8761–8766.
38. Krebs CF, Paust HJ, Krohn S, et al. Autoimmune renal disease is exacerbated by S1P-receptor-1-dependent intestinal Th17 cell migration to the kidney.
Immunity 2016;45:1078–1092.
39. Velden J, Paust HJ, Hoxha E, et al. Renal IL-17 expression in human ANCA-associated glomerulonephritis.
Am J Physiol Renal Physiol 2012;302:F1663–F1673.
40. Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis.
Nephrol Dial Transplant 2010;25:2209–2217.
41. Wątorek E, Klinger M. IL-17A as a potential biomarker of IgA nephropathy.
Pol Arch Med Wewn 2015;125:204–206.
42. Jen HY, Chuang YH, Lin SC, Chiang BL, Yang YH. Increased serum interleukin-17 and peripheral Th17 cells in children with acute Henoch-Schönlein purpura.
Pediatr Allergy Immunol 2011;22:862–868.
43. Wang L, Li Q, Wang L, et al. The role of Th17/IL-17 in the pathogenesis of primary nephrotic syndrome in children.
Kidney Blood Press Res 2013;37:332–345.
44. Liu LL, Qin Y, Cai JF, et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome.
Clin Immunol 2011;139:314–320.
45. Loverre A, Tataranni T, Castellano G, et al. IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibody-mediated rejection.
Am J Transplant 2011;11:1248–1259.
46. Hsieh HG, Loong CC, Lui WY, Chen A, Lin CY. IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection.
Transpl Int 2001;14:287–298.
47. de Menezes Neves PD, Machado JR, dos Reis MA, Faleiros AC, de Lima Pereira SA, Rodrigues DB. Distinct expression of interleukin 17, tumor necrosis factor α, transforming growth factor β, and forkhead box P3 in acute rejection after kidney transplantation.
Ann Diagn Pathol 2013;17:75–79.
48. Millán O, Rafael-Valdivia L, San Segundo D, et al. Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study.
Clin Immunol 2014;154:141–154.
49. Matignon M, Aissat A, Canoui-Poitrine F, et al. Th-17 alloimmune responses in renal allograft biopsies from recipients of kidney transplants using extended criteria donors during acute T cell-mediated rejection.
Am J Transplant 2015;15:2718–2725.
50. Chung BH, Kim KW, Kim BM, Doh KC, Cho ML, Yang CW. Increase of Th17 cell phenotype in kidney transplant recipients with chronic allograft dysfunction.
PLoS One 2015;10:e0145258.
51. Maravitsa P, Adamopoulou M, Pistiki A, Netea MG, Louis K, Giamarellos-Bourboulis EJ. Systemic over-release of interleukin-17 in acute kidney injury after septic shock: clinical and experimental evidence.
Immunol Lett 2016;178:68–76.
52. Coppock GM, Aronson LR, Park J, et al. Loss of IL-27Rα results in enhanced tubulointerstitial fibrosis associated with elevated th17 responses.
J Immunol 2020;205:377–386.
53. Chung BH, Kim KW, Sun IO, et al. Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients.
Immunol Lett 2012;141:181–189.
54. Zhang C, Xiao C, Wang P, et al. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy.
Hum Immunol 2014;75:289–296.
55. Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.
Nat Med 2019;25:805–813.
56. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction.
Hypertension 2010;55:500–507.
57. Yao W, Sun Y, Wang X, Niu K. Elevated serum level of interleukin 17 in a population with prehypertension.
J Clin Hypertens (Greenwich) 2015;17:770–774.
58. Simundic T, Jelakovic B, Dzumhur A, et al. Interleukin 17A and toll-like receptor 4 in patients with arterial hypertension.
Kidney Blood Press Res 2017;42:99–108.
59. Hosseini A, Dolati S, Hashemi V, Abdollahpour-Alitappeh M, Yousefi M. Regulatory T and T helper 17 cells: Their roles in preeclampsia.
J Cell Physiol 2018;233:6561–6573.
60. Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications.
Cold Spring Harb Perspect Biol 2018;10:a028522.
61. Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis.
Clin Immunol 2017;185:95–99.
62. Gan PY, Chan A, Ooi JD, et al. Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis.
Kidney Int 2019;96:1121–1133.
63. Gan PY, Steinmetz OM, Tan DS, et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis.
J Am Soc Nephrol 2010;21:925–931.
64. Hünemörder S, Treder J, Ahrens S, et al. TH1 and TH17 cells promote crescent formation in experimental autoimmune glomerulonephritis.
J Pathol 2015;237:62–71.
65. Summers SA, Odobasic D, Khouri MB, et al. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.
Clin Exp Immunol 2014;176:341–350.
66. Steinmetz OM, Summers SA, Gan PY, Semple T, Holdsworth SR, Kitching AR. The Th17-defining transcription factor RORγt promotes glomerulonephritis.
J Am Soc Nephrol 2011;22:472–483.
67. Paust HJ, Turner JE, Riedel JH, et al. Chemokines play a critical role in the cross-regulation of Th1 and Th17 immune responses in murine crescentic glomerulonephritis.
Kidney Int 2012;82:72–83.
68. Tulone C, Giorgini A, Freeley S, Coughlan A, Robson MG. Transferred antigen-specific T(H)17 but not T(H)1 cells induce crescentic glomerulonephritis in mice.
Am J Pathol 2011;179:2683–2690.
69. Steinmetz OM, Turner JE, Paust HJ, et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
J Immunol 2009;183:4693–4704.
70. Lu G, Zhang X, Shen L, et al. CCL20 secreted from IgA1-stimulated human mesangial cells recruits inflammatory Th17 cells in IgA nephropathy.
PLoS One 2017;12:e0178352.
71. Nakagiri T, Inoue M, Minami M, Shintani Y, Okumura M. Immunology mini-review: the basics of T(H)17 and interleukin-6 in transplantation.
Transplant Proc 2012;44:1035–1040.
72. Chung BH, Yang CW, Cho ML. Clinical significance of Th17 cells in kidney transplantation.
Korean J Intern Med 2018;33:860–866.
73. Nova-Lamperti E, Romano M, Christakoudi S, et al. Reduced TCR signaling contributes to impaired Th17 responses in tolerant kidney transplant recipients.
Transplantation 2018;102:e10–e17.
74. Min SI, Ha J, Park CG, et al. Sequential evolution of IL-17 responses in the early period of allograft rejection.
Exp Mol Med 2009;41:707–716.
75. Zhou Y, Yang X, Zhang H, Jiang J. The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats.
Transplantation 2015;99:1126–1131.
76. Itoh S, Kimura N, Axtell RC, et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion.
Circulation 2011;124:S187–S196.
77. Mortazavi H, Soltani-Zangbar MS, Eghbal-Fard S, et al. Cytokine profile, Treg/Th17 cell frequency changes during different posttransplantational time points in patients undergoing renal transplantation.
J Cell Physiol 2019;234:20935–20943.
78. Abadja F, Atemkeng S, Alamartine E, Berthoux F, Mariat C. Impact of mycophenolic acid and tacrolimus on Th17-related immune response.
Transplantation 2011;92:396–403.
79. Chung BH, Kim BM, Doh KC, et al. Suppressive effect of 1α,25-dihydroxyvitamin D3 on Th17-immune responses in kidney transplant recipients with tacrolimus-based immunosuppression.
Transplantation 2017;101:1711–1719.
80. Kinsey GR, Sharma R, Okusa MD. Regulatory T cells in AKI.
J Am Soc Nephrol 2013;24:1720–1726.
81. Gharaie Fathabad S, Kurzhagen JT, Sadasivam M, et al. T lymphocytes in acute kidney injury and repair.
Semin Nephrol 2020;40:114–125.
82. Yokota N, Burne-Taney M, Racusen L, Rabb H. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury.
Am J Physiol Renal Physiol 2003;285:F319–F325.
83. de Bragança AC, Volpini RA, Mehrotra P, Andrade L, Basile DP. Vitamin D deficiency contributes to vascular damage in sustained ischemic acute kidney injury.
Physiol Rep 2016;4:e12829.
84. Mehrotra P, Collett JA, McKinney SD, Stevens J, Ivancic CM, Basile DP. IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion: compensatory role of natural killer cells in athymic rats.
Am J Physiol Renal Physiol 2017;312:F385–F397.
85. Lee JW, Bae E, Kwon SH, et al. Transcriptional modulation of the T helper 17/interleukin 17 axis ameliorates renal ischemia-reperfusion injury.
Nephrol Dial Transplant 2019;34:1481–1498.
86. Mehrotra P, Ullah MM, Collett JA, et al. Mutation of RORγT reveals a role for Th17 cells in both injury and recovery from renal ischemia-reperfusion injury.
Am J Physiol Renal Physiol 2020;319:F796–F808.
87. Luo CJ, Luo F, Zhang L, et al. Knockout of interleukin-17A protects against sepsis-associated acute kidney injury.
Ann Intensive Care 2016;6:56.
88. Chan AJ, Alikhan MA, Odobasic D, et al. Innate IL-17A-producing leukocytes promote acute kidney injury via inflammasome and Toll-like receptor activation.
Am J Pathol 2014;184:1411–1418.
89. Wang F, Yin J, Lin Y, et al. IL-17C has a pathogenic role in kidney ischemia/reperfusion injury.
Kidney Int 2020;97:1219–1229.
90. Ullah MM, Basile DP. Role of renal hypoxia in the progression from acute kidney injury to chronic kidney disease.
Semin Nephrol 2019;39:567–580.
91. Mehrotra P, Patel JB, Ivancic CM, Collett JA, Basile DP. Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism.
Kidney Int 2015;88:776–784.
92. Pechman KR, Basile DP, Lund H, Mattson DL. Immune suppression blocks sodium-sensitive hypertension following recovery from ischemic acute renal failure.
Am J Physiol Regul Integr Comp Physiol 2008;294:R1234–R1239.
93. Kim YG, Kim EY, Ihm CG, et al. Gene polymorphisms of interleukin-17 and interleukin-17 receptor are associated with end-stage kidney disease.
Am J Nephrol 2012;36:472–477.
94. Chi HH, Hua KF, Lin YC, et al. IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23/IL-17 axis in renal inflammation and fibrosis.
J Am Soc Nephrol 2017;28:2022–2037.
95. Rodrigues-Díez R, Rodrigues-Díez RR, Rayego-Mateos S, et al. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response.
Lab Invest 2013;93:812–824.
96. Ramani K, Tan RJ, Zhou D, et al. IL-17 receptor signaling negatively regulates the development of tubulointerstitial fibrosis in the kidney.
Mediators Inflamm 2018;2018:5103672.
97. Pindjakova J, Hanley SA, Duffy MM, et al. Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction.
Kidney Int 2012;81:379–390.
98. Xu Y, Lin H, Zheng W, et al. Matrine ameliorates adriamycin-induced nephropathy in rats by enhancing renal function and modulating Th17/Treg balance.
Eur J Pharmacol 2016;791:491–501.
99. Muallem G, Aronson L, Hunter CA, et al. The endogenous regulator IL-27 suppresses Th2 and Th17 responses in the kidney to ameliorate renal fibrosis in a model of obstructive kidney disease.
J Immunol 2017;198(1 Suppl):220.17.
100. Lavoz C, Rayego-Mateos S, Orejudo M, et al. Could IL-17A be a novel therapeutic target in diabetic nephropathy?
J Clin Med 2020;9:272.
101. Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice.
Diabetes 2009;58:1302–1311.
102. Kim SM, Lee SH, Lee A, et al. Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression.
Transl Res 2015;166:375–383.
103. Ma J, Li YJ, Chen X, Kwan T, Chadban SJ, Wu H. Interleukin 17A promotes diabetic kidney injury.
Sci Rep 2019;9:2264.
104. Lavoz C, Matus YS, Orejudo M, et al. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
Kidney Int 2019;95:1418–1432.
105. Rodríguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all.
Am J Physiol Renal Physiol 2004;286:F606–F616.
106. Abais-Battad JM, Rudemiller NP, Mattson DL. Hypertension and immunity: mechanisms of T cell activation and pathways of hypertension.
Curr Opin Nephrol Hypertens 2015;24:470–474.
107. Abais-Battad JM, Lund H, Fehrenbach DJ, Dasinger JH, Mattson DL. Rag1-null Dahl SS rats reveal that adaptive immune mechanisms exacerbate high protein-induced hypertension and renal injury.
Am J Physiol Regul Integr Comp Physiol 2018;315:R28–R35.
108. Rodríguez-Iturbe B, Pons H, Quiroz Y, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure.
Kidney Int 2001;59:2222–2232.
109. Wade B, Petrova G, Mattson DL. Role of immune factors in angiotensin II-induced hypertension and renal damage in Dahl salt-sensitive rats.
Am J Physiol Regul Integr Comp Physiol 2018;314:R323–R333.
110. Amador CA, Barrientos V, Peña J, et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Hypertension 2014;63:797–803.
111. Chiasson VL, Pakanati AR, Hernandez M, Young KJ, Bounds KR, Mitchell BM. Regulatory T-cell augmentation or interleukin-17 inhibition prevents calcineurin inhibitor-induced hypertension in mice.
Hypertension 2017;70:183–191.
112. Cornelius DC, Hogg JP, Scott J, et al. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy.
Hypertension 2013;62:1068–1073.
113. Rudemiller NP, Crowley SD. Interactions between the immune and the renin-angiotensin systems in hypertension.
Hypertension 2016;68:289–296.
114. Faraco G, Brea D, Garcia-Bonilla L, et al. Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response.
Nat Neurosci 2018;21:240–249.
115. Luo T, Ji WJ, Yuan F, et al. Th17/Treg imbalance induced by dietary salt variation indicates inflammation of target organs in humans.
Sci Rep 2016;6:26767.
116. Dar HY, Singh A, Shukla P, et al. High dietary salt intake correlates with modulated Th17-Treg cell balance resulting in enhanced bone loss and impaired bone-microarchitecture in male mice.
Sci Rep 2018;8:2503.
117. Haase S, Wilck N, Kleinewietfeld M, Müller DN, Linker RA. Sodium chloride triggers Th17 mediated autoimmunity.
J Neuroimmunol 2019;329:9–13.
118. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells.
Nature 2013;496:518–522.
119. Schatz V, Neubert P, Schröder A, et al. Elementary immunology: Na+ as a regulator of immunity.
Pediatr Nephrol 2017;32:201–210.
120. Evans RDR, Antonelou M, Sathiananthamoorthy S, et al. Inherited salt-losing tubulopathies are associated with immunodeficiency due to impaired IL-17 responses.
Nat Commun 2020;11:4368.
121. Liu J, Krautzberger AM, Sui SH, et al. Cell-specific translational profiling in acute kidney injury.
J Clin Invest 2014;124:1242–1254.
122. Norlander AE, Saleh MA, Kamat NV, et al. Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension.
Hypertension 2016;68:167–174.
123. Kamat NV, Thabet SR, Xiao L, et al. Renal transporter activation during angiotensin-II hypertension is blunted in interferon-γ
-/- and interleukin-17A
-/- mice.
Hypertension 2015;65:569–576.
124. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression.
J Am Soc Nephrol 2015;26:1765–1776.
125. Kirita Y, Wu H, Uchimura K, Wilson PC, Humphreys BD. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury.
Proc Natl Acad Sci U S A 2020;117:15874–15883.
126. Weng CH, Li YJ, Wu HH, et al. Interleukin-17A induces renal fibrosis through the ERK and Smad signaling pathways.
Biomed Pharmacother 2020;123:109741.
127. Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension.
Cardiovasc Res 2013;97:696–704.
128. Orejudo M, García-Redondo AB, Rodrigues-Diez RR, et al. Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation.
Clin Sci (Lond) 2020;134:513–527.
129. Roussel L, Houle F, Chan C, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation.
J Immunol 2010;184:4531–4537.
130. Yuan S, Zhang S, Zhuang Y, Zhang H, Bai J, Hou Q. Interleukin-17 stimulates STAT3-mediated endothelial cell activation for neutrophil recruitment.
Cell Physiol Biochem 2015;36:2340–2356.
131. Wojkowska DW, Szpakowski P, Glabinski A. Interleukin 17A promotes lymphocytes adhesion and induces CCL2 and CXCL1 release from brain endothelial cells.
Int J Mol Sci 2017;18:1000.
132. Kramann R, DiRocco DP, Humphreys BD. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease.
J Pathol 2013;231:273–289.
133. Evasovic JM, Singer CA. Regulation of IL-17A and implications for TGF-β1 comodulation of airway smooth muscle remodeling in severe asthma.
Am J Physiol Lung Cell Mol Physiol 2019;316:L843–L868.
134. Lauridsen HM, Pellowe AS, Ramanathan A, et al. Tumor necrosis factor-α and IL-17A activation induces pericyte-mediated basement membrane remodeling in human neutrophilic dermatoses.
Am J Pathol 2017;187:1893–1906.
135. Liu R, Lauridsen HM, Amezquita RA, et al. IL-17 promotes neutrophil-mediated immunity by activating microvascular pericytes and not endothelium.
J Immunol 2016;197:2400–2408.
136. Zhang J, Qiao Q, Liu M, et al. IL-17 promotes scar formation by inducing macrophage infiltration.
Am J Pathol 2018;188:1693–1702.
137. Ge S, Hertel B, Susnik N, et al. Interleukin 17 receptor A modulates monocyte subsets and macrophage generation in vivo.
PLoS One 2014;9:e85461.
138. de la Paz Sánchez-Martínez M, Blanco-Favela F, Mora-Ruiz MD, Chávez-Rueda AK, Bernabe-García M, Chávez-Sánchez L. IL-17-differentiated macrophages secrete pro-inflammatory cytokines in response to oxidized low-density lipoprotein.
Lipids Health Dis 2017;16:196.
139. Nishikawa K, Seo N, Torii M, et al. Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation.
PLoS One 2014;9:e108494.
140. Zizzo G, Cohen PL. IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids.
J Immunol 2013;190:5237–5246.
141. Ramani K, Zhou D, Tan R, Liu Y, Gaffen S, Biswas PS. Disruption of interleukin-17 receptor A (IL-17RA) gene in mice aggravates renal interstitial fibrosis in obstructive nephropathy.
J Immunol 2016;196(1 Suppl):51.24.
142. Krebs CF, Lange S, Niemann G, et al. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin ii-induced hypertension.
Hypertension 2014;63:565–571.
143. Sun B, Wang H, Zhang L, et al. Role of interleukin 17 in TGF-β signaling-mediated renal interstitial fibrosis.
Cytokine 2018;106:80–88.
144. Corneth OB, Schaper F, Luk F, et al. Lack of IL-17 receptor A signaling aggravates lymphoproliferation in C57BL/6 lpr mice.
Sci Rep 2019;9:4032.
145. Mohamed R, Jayakumar C, Chen F, et al. Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis.
J Am Soc Nephrol 2016;27:745–765.
146. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis.
Expert Opin Investig Drugs 2013;22:993–1005.
147. Tian C, Du L, Zhou Y, Li M. Store-operated CRAC channel inhibitors: opportunities and challenges.
Future Med Chem 2016;8:817–832.